Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:CMPS NASDAQ:SPRY NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$36.59-4.5%$40.24$26.20▼$63.50$1.76B1.43809,292 shs856,298 shsCMPSCOMPASS Pathways$4.36-2.7%$4.01$2.25▼$8.54$429.82M2.172.35 million shs718,263 shsSPRYARS Pharmaceuticals$17.98+1.0%$16.61$9.45▼$18.90$1.75B0.91.23 million shs1.03 million shsSRPTSarepta Therapeutics$16.26-2.9%$22.54$10.41▼$145.00$1.65B0.4621.53 million shs13.20 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-4.53%-2.70%-6.75%-3.22%-12.35%CMPSCOMPASS Pathways-2.68%+10.66%+31.72%+15.93%-37.89%SPRYARS Pharmaceuticals+1.01%+0.56%+5.21%+33.28%+83.84%SRPTSarepta Therapeutics-2.93%-2.93%-6.12%-55.48%-88.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGEApogee Therapeutics2.6742 of 5 stars3.50.00.00.04.04.20.0CMPSCOMPASS Pathways2.8302 of 5 stars3.44.00.00.02.90.80.6SPRYARS Pharmaceuticals3.2362 of 5 stars3.62.00.00.02.64.20.6SRPTSarepta Therapeutics4.6259 of 5 stars4.12.00.04.23.01.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 3.00Buy$99.00170.54% UpsideCMPSCOMPASS Pathways 2.86Moderate Buy$16.29273.53% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.0072.41% UpsideSRPTSarepta Therapeutics 2.10Hold$49.12202.09% UpsideCurrent Analyst Ratings BreakdownLatest CMPS, APGE, SPRY, and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/4/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $40.008/1/2025CMPSCOMPASS PathwaysCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.007/29/2025SRPTSarepta TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$22.007/29/2025SRPTSarepta TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform7/29/2025SRPTSarepta TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Perform ➝ Market Perform$25.00 ➝ $50.007/29/2025SRPTSarepta TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $20.007/29/2025SRPTSarepta TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$15.007/29/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell7/29/2025SRPTSarepta TherapeuticsSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform$13.007/29/2025SRPTSarepta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$30.00 ➝ $37.007/29/2025SRPTSarepta TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$24.00(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/ACMPSCOMPASS PathwaysN/AN/AN/AN/A$1.69 per shareN/ASPRYARS Pharmaceuticals$89.15M19.81$0.01 per share2,101.96$2.64 per share6.81SRPTSarepta Therapeutics$1.90B0.84$2.36 per share6.88$15.99 per share1.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$182.15M-$3.60N/AN/AN/AN/A-28.35%-26.98%8/11/2025 (Estimated)CMPSCOMPASS Pathways-$155.12M-$1.84N/AN/AN/AN/A-87.89%-57.77%N/ASPRYARS Pharmaceuticals$8M-$0.16N/AN/AN/A-16.11%-6.94%-5.60%8/13/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$2.69N/A1.49N/A-11.12%-14.88%-5.12%N/ALatest CMPS, APGE, SPRY, and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SPRYARS Pharmaceuticals-$0.42N/AN/AN/A$12.92 millionN/A8/11/2025Q2 2025APGEApogee Therapeutics-$1.08N/AN/AN/AN/AN/A7/31/2025Q2 2025CMPSCOMPASS Pathways-$0.37-$0.38-$0.01-$0.41N/AN/A5/14/2025Q1 2025SPRYARS Pharmaceuticals-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/8/2025Q1 2025CMPSCOMPASS Pathways-$0.47-$0.44+$0.03-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A15.8215.82CMPSCOMPASS Pathways0.168.828.82SPRYARS Pharmaceuticals0.3011.0010.74SRPTSarepta Therapeutics1.004.022.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%CMPSCOMPASS Pathways46.19%SPRYARS Pharmaceuticals68.16%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics42.77%CMPSCOMPASS Pathways3.93%SPRYARS Pharmaceuticals33.50%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9146.05 million26.35 millionOptionableCMPSCOMPASS Pathways12095.94 million92.17 millionOptionableSPRYARS Pharmaceuticals9098.21 million65.31 millionOptionableSRPTSarepta Therapeutics1,37298.28 million90.71 millionOptionableCMPS, APGE, SPRY, and SRPT HeadlinesRecent News About These CompaniesSRPT SHAREHOLDERS: Sarepta Therapeutics Stock Drop Triggers Securities Fraud Class Action – Contact BFA Law by August 25 if You Lost Money (NASDAQ:SRPT)1 hour ago | globenewswire.comCautious Outlook on Sarepta Therapeutics Amid Financial Strain and ELEVIDYS Challenges2 hours ago | tipranks.comDecoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT InsightAugust 6 at 12:39 AM | gurufocus.comSarepta rises on strong quarterly earnings and revenueAugust 6 at 10:09 PM | msn.comSarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to SayAugust 6 at 8:01 PM | zacks.comSarepta Therapeutics: Hold Rating Amid Financial Gains and Clinical UncertaintiesAugust 6 at 7:39 PM | tipranks.comSarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue EstimatesAugust 6 at 6:45 PM | zacks.comSarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing ...August 6 at 6:13 PM | gurufocus.comSarepta Therapeutics (SRPT) Surges on Strong Q2 EarningsAugust 6 at 6:13 PM | gurufocus.comSarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens BermanAugust 6 at 5:56 PM | globenewswire.comSarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate ...August 6 at 5:13 PM | gurufocus.comSarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate ...August 6 at 5:12 PM | gurufocus.comSarepta reportedly hired Trump-linked lobbying firm after gene therapy deathsAugust 6 at 5:08 PM | msn.comSarepta Therapeutics (SRPT) Faces Regulatory and Financial ChallengesAugust 6 at 4:13 PM | gurufocus.comSarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate DevelopmentsAugust 6 at 4:05 PM | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPTAugust 6 at 10:00 AM | prnewswire.comRaiffeisen Bank International AG Purchases 16,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)August 6 at 5:07 AM | marketbeat.comSAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the FirmAugust 5 at 7:26 PM | globenewswire.comSarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff MotionAugust 5 at 6:00 PM | globenewswire.comLevi & Korsinsky Notifies Shareholders of Sarepta Therapeutics, Inc.(SRPT) of a Class Action Lawsuit and an Upcoming DeadlineAugust 5 at 4:10 PM | globenewswire.comWhat to Expect from Sarepta Therapeutics's EarningsAugust 5 at 3:20 PM | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPS, APGE, SPRY, and SRPT Company DescriptionsApogee Therapeutics NASDAQ:APGE$36.59 -1.74 (-4.53%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$36.78 +0.18 (+0.50%) As of 07:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.COMPASS Pathways NASDAQ:CMPS$4.36 -0.12 (-2.68%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$4.39 +0.03 (+0.80%) As of 08:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.ARS Pharmaceuticals NASDAQ:SPRY$17.98 +0.18 (+1.01%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$18.25 +0.27 (+1.50%) As of 08:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.Sarepta Therapeutics NASDAQ:SRPT$16.26 -0.49 (-2.93%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$17.61 +1.35 (+8.30%) As of 08:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.